In this issue:
Hypophosphataemia after intravenous iron administration
Cusatuzumab + azacitidine in newly diagnosed AML
Combinations superior in Sézary syndrome
Defibrotide for preventing CAR T-cell-associated neurotoxicity
Long-term outcomes for Langerhans cell histiocytosis
Azacitidine, lenalidomide and DLI for myeloid malignancy post-transplant relapse
Cumulative post-transplant brentuximab vedotin dose in Hodgkin lymphoma
Improvements across years in AML/MDS survival after allogeneic SCT
Treating severe aplastic anaemia in resource-limited setting
Identifying risks following CAR T-cells for mantle cell lymphoma
Please login below to download this issue (PDF)